Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1839

Nov 14, 2019

Landmark Summits Reveal the Future of National Economies

Posted by in categories: biotech/medical, business, economics, finance, governance, life extension, policy, robotics/AI

Deep Knowledge Group is delighted to have supported and participated in the landmark International Longevity Policy and Governance and AI for Longevity Summits that took place on November 12th at King’s College London, which gathered an unprecedented density and diversity of speakers and panelists at the intersection of Longevity, AI, Policy and Finance. The summits were organized by Longevity International UK and the AI Longevity Consortium at King’s College London, with the strategic support of Deep Knowledge Group, Aging Analytics Agency, Ageing Research at King’s (ARK) and the Biogerontology Research Foundation. Together they managed to attract the interest of major financial corporations, insurance companies, investment banks, Pharma and Tech corporations, and representatives of international governmental bodies, organisations and embassies, as well as leading media, and featured presentations and panel discussions from top executives and directors of Prudential, Barclays Business UK, HSBC, AXA, L&G, Longevity. Capital, Longevity Vision Fund, Juvenescence, the UK Office of AI, Microsoft, NVIDIA, Babylon Health, Huawei Europe, Insilico Medicine, Longevity International UK, the Longevity AI Consortium and others.


November 14, 2019, London, UK: Deep Knowledge Group executives Dmitry Kaminksiy and Eric Kihlstrom spoke at a landmark one-day event held yesterday at King’s College London with the strategic support Deep Knowledge Group. The event united two Longevity-themed summits under the shared strategic agenda of enabling a paradigm shift from treatment to prevention and from prevention to Precision Health via the synergistic efforts of science, industry, AI, policy and governance, to enable the UK to become an international leader in Healthy Longevity.

Nov 14, 2019

Highly processed food has been linked to cancer

Posted by in categories: biotech/medical, food

Read more

Nov 14, 2019

UPS and CVS deliver prescription medicine via drone to US residential customers for the first time

Posted by in categories: biotech/medical, drones

UPS is rolling along with its drone delivery program, working with partner CVS Pharmacy to deliver prescription drugs to customer doorsteps via its newly deployed commercial drones. UPS delivered medications to two paying customers on November 1 using the Matternet M2 drone system that the logistics company is using in partnership with Matternet…

Nov 14, 2019

Realistic arm prosthetic

Posted by in categories: 3D printing, biotech/medical, cyborgs, robotics/AI

This 3D-printed robotic arm could be the most advanced and most realistic yet.

Nov 14, 2019

The world’s first medically approved 3D-printed bionic arm is now available in the UK, USA, France, Spain and Ireland for children and adults with below-elbow limb differences

Posted by in categories: 3D printing, biotech/medical, cyborgs, transhumanism

More countries coming very soon! Start your bionic journey here: http://

Nov 14, 2019

HyperStealth Biotechnology Creates Real ‘Invisibility Cloak’

Posted by in category: biotech/medical

Here’s how HyperStealth Biotechnology Corp.’s ‘invisibility cloak’ works ✨.

Nov 14, 2019

The ‘post-antibiotic era’ is here: Drug-resistant ‘superbugs’ sicken 2.8M and kill 35K each year, CDC says

Posted by in category: biotech/medical

A new CDC report sets a baseline of infections and deaths from antibiotic-resistant germs and outlines strategies to slow drug-resistant infections.

Nov 14, 2019

Sleep duration predicts death risk in diabetes and hypertension

Posted by in category: biotech/medical

An analysis of data from 1,654 people suggests that sleep duration may help predict early death risk in people with type 2 diabetes or hypertension.

Nov 14, 2019

Parkinson’s Gut Bacteria Studies Differ in Findings, Methods, Review Says

Posted by in categories: biotech/medical, neuroscience

Studies on gut bacteria in Parkinson’s disease differ in their findings and important methodological details, according to a new review that highlights these differences and proposes strategies to mitigate them in the future.

The study, titled “ Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review,” was published in the Journal of Parkinson’s Disease.

Although Parkinson’s is often thought of as a disorder of the brain, the gut likely plays an important role in the disease, but it has only been seriously studied in recent years. A number of studies have recently focused on how the gut microbiome — the bacteria that live inside the intestines — might impact Parkinson’s.

Nov 14, 2019

Toxic gut bacteria make alcohol-triggered liver disease more deadly

Posted by in category: biotech/medical

For a heavy drinker whose liver has been destroyed by alcohol, an organ transplant is often the only realistic option. But because of donor liver shortages and rules that withhold them from people who have not shed their alcohol addiction, many go without. Tens of thousands die from alcoholic liver disease each year in the United States—and some go downhill much faster than others. Now, scientists have found a reason for this disparity: a toxin produced by some strains of a common gut bacterium. Working in mice, they have also tested a potential therapy, based on bacteria-destroying viruses found lurking in the sewer.

Why some drinkers with liver disease fare much worse than others “has always been a conundrum,” says Jasmohan Bajaj, a gastroenterologist and liver specialist at Virginia Commonwealth University in Richmond. The bacterium Enterococcus faecalis offers an explanation, Bernd Schnabl, a gastroenterologist at the University of California, San Diego (UCSD), School of Medicine, and colleagues report this week in Nature. In fecal samples from patients with alcoholic liver disease, levels of it were 2700 times higher than in nondrinkers, although the mere quantity didn’t correlate with a person’s outcome. Instead, the researchers identified a cell-destroying toxin called cytolysin produced by select strains of E. faecalis as the likely reason that some patients with alcoholic liver disease had severe symptoms.

Fewer than 5% of healthy people carry the toxinmaking strains, but the group found them in 30% of the people hospitalized with alcoholic liver disease whom they tested. And those patients had a much higher mortality rate within 180 days of admission—89% of the cytolysin-positive patients died compared with only 3.8% of the other patients. “Cytolysin is a factor that really drives mortality and liver disease severity,” Schnabl says.